COVID-19-ассоциированный легочный аспергиллез: от инвазивной к хронической форме.
DOI:
https://doi.org/10.52692/1857-0011.2021.3-71.50Ключевые слова:
SARS-CoV-2, COVID-19, COVID-ИА, Aspergillus, аспергиллезАннотация
COVID-19-ассоциированный инвазивный легочный аспергиллез (COVID-ИА) является потенциальным инфекционным осложнением, поражающим тяжелобольных пациентов с инфекцией SARS-CoV-2. В связи с растущим числом случаев и высоким уровнем смертности существует острая необходимость в дополнительнойинформации о взаимодействии между SARS ‐ CoV ‐ 2 и Aspergillus spp., а также о лечении COVID-ИА.Представляем случай с диагнозом тяжелой формы COVID-ИА, который подчеркивает проблему диагностикии лечения, с последующим 6-месячным мониторингом поражений легких.
Библиографические ссылки
Schauwvlieghe, A., et al., Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med, 2018. 6(10): p. 782-792.
Wauters, J., et al., Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients:a retrospective study. Intensive Care Med, 2012. 38(11):p. 1761-8.
Arastehfar, A., et al., COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment. J Fungi (Basel), 2020. 6(2).
Wu, C., et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 2020. 180(7): p. 934-943.
Suleyman, G., et al., Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open, 2020. 3(6): p. e2012270.
Zhu, X., et al., Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res, 2020. 285: p. 198005.
Borman, A.M., et al., COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory. J Clin Microbiol, 2020. 59(1).
Alanio, A., et al., Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med, 2020. 8(6): p. e48-e49.
van Arkel, A.L.E., et al., COVID-19-associated Pulmonary Aspergillosis. Am J Respir Crit Care Med, 2020. 202(1): p. 132-135.
Rutsaert, L., et al., COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care, 2020. 10(1): p. 71.
Nasir, N., et al., COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses, 2020. 63(8): p. 766-770.
Bartoletti, M., et al., Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis, 2020.
Gangneux, J.P., et al., Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience. J Fungi (Basel), 2020. 6(3).
Koehler, P., et al., COVID-19 associated pulmonary aspergillosis. Mycoses, 2020. 63(6): p. 528-534.
Koehler, P., et al., Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis, 2021. 21(6): p. e149-e162.
White, P.L., Diagnosis of invasive fungal disease in coronavirus disease 2019: approaches and pitfalls. Curr Opin Infect Dis, 2021. 34(6): p. 573-580.
Cebotaru, A., et al. Aspergiloza pulmonară asociată infecției prin COVID-19 (revista literaturii). Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2021. 1(69): p. 170-173.
Swain, S., et al., COVID-19-associated subacute invasive pulmonary aspergillosis. Mycoses, 2021.
Toniati, P., et al., Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev, 2020. 19(7): p. 102568.
Cenci, E., et al., Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. J Infect Dis, 2001. 184(5): p. 610-7.
Antonov, V.N., et al., [Experience of olokizumab use in COVID-19 patients]. Ter Arkh, 2020. 92(12): p. 148-154.
Ezeokoli, O.T., O. Gcilitshana, and C.H. Pohl, Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants. J Fungi (Basel), 2021. 7(7).
Jenks, J.D., H.H. Nam, and M. Hoenigl, Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches. Mycoses, 2021. 64(9): p. 1002-1014.
Загрузки
Опубликован
Выпуск
Раздел
Лицензия
Copyright (c) 2022 Вестник Академии Наук Молдовы. Медицина
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
